Video library
Explore videos featuring oncologists offering their expert insights on key topics related to TEVIMBRA, including clinical data from phase 3 trials, product design, dosing, safety, and access.
Dosing Flexibility with TEVIMBRA
Navigating Formulary Access to TEVIMBRA
Dani Castillo, MD, discusses the process for obtaining formulary approval for TEVIMBRA in her practice.
Overall Survival Data and the National Comprehensive Cancer Network® (NCCN®) Recommendations
PD-L1 Testing (TAP vs CPS)
RATIONALE-305 OS Subgroup Analyses
Dani Castillo, MD, reviews subgroup analyses of overall survival, which included positive overall survival with TEVIMBRA + chemotherapy in patients with peritoneal metastases.2
RATIONALE-305 Study Design
Ronan J. Kelly, MD, MBA, reviews RATIONALE-305, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable or metastatic, HER2-negative GC or GEJC.
RATIONALE-306 Study Design
Marica Cruz-Correa, MD, PhD, AGAF, FASGE, reviews RATIONALE-306, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable, advanced or metastatic ESCC.
TEVIMBRA Mechanism of Action
Ronan J. Kelly, MD, MBA, discusses how TEVIMBRA is a unique PD-1 inhibitor.
1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand 1.
References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Sonbol MB, Rha SY, Xu RH, et al. Abstract and poster presented at: ASCO Gastrointestinal Cancers Symposium; January 8-10, 2026. San Francisco, CA. Abstract 378, poster D9.